1. Home
  2. ALDX vs NSRX Comparison

ALDX vs NSRX Comparison

Compare ALDX & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$0.64

Market Cap

39.2M

Sector

Health Care

ML Signal

HOLD

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.53

Market Cap

37.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALDX
NSRX
Founded
2004
2019
Country
United States
Israel
Employees
6
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.2M
37.1M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
ALDX
NSRX
Price
$0.64
$3.53
Analyst Decision
Buy
Buy
Analyst Count
6
2
Target Price
$6.60
★ $19.67
AVG Volume (30 Days)
★ 1.8M
23.8K
Earning Date
11-04-2026
08-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 40.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.98
52 Week High
$5.93
$9.50

Technical Indicators

Market Signals
Indicator
ALDX
NSRX
Relative Strength Index (RSI) 26.32 50.98
Support Level N/A $2.97
Resistance Level $1.58 $3.60
Average True Range (ATR) 0.08 0.27
MACD -0.01 -0.01
Stochastic Oscillator 7.12 48.14

Price Performance

Historical Comparison
ALDX
NSRX

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: